I.P. Pavlov Russian Medical Biological HeraldI.P. Pavlov Russian Medical Biological HeraldРоссийский медико-биологический вестник имени академика И.П. Павлова0204-34752500-2546Eco-Vector5809510.23888/PAVLOVJ2020284593-604ReviewНаучные обзорыReview ArticleSubstance-induced psychosis and schizophrenia: the interaction pointИндуцированные наркотическими веществами психозы и шизофрения: точки со-прикосновения药物诱发的精神分裂症和精神分裂症：接触点https://orcid.org/0000-0002-2791-7180N-9456-2016FedotovIlya А.ФедотовИлья Андреевич
Russian Federation

МD, PhD, Associate Professor of the Department of Psychiatry

к.м.н., доцент кафедры психиатрии

ilyafdtv@yandex.ruhttps://orcid.org/0000-0002-6051-8309I-2362-2019QuattroneDiegoКватронДиего
United Kingdom

Researcher in MRC Social, Genetic and Developmental Psychiatry Centre

научный сотрудник Центра социальных, генетических и связанных с развитием исследований в психиатрии

ilyafdtv@yandex.ruhttps://orcid.org/0000-0001-7803-3388AAG-2198-20193887-5475ShustovDmitri I.ШустовДмитрий Иванович
Russian Federation

МD, PhD, Professor, Head of the Department of Psychiatry

д.м.н., профессор, зав. кафедрой психиатрии

ilyafdtv@yandex.ruRyazan State Medical UniversityФГБОУ ВО Рязанский государственный медицинский университет им. акад. И.П. Павлова Минздрава РоссииSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College LondonЦентр социальных, генетических и связанных с развитием исследований в психиатрии, Королевский Колледж151220202845936041201202112012021Copyright ©; 2021, Eco-VectorCopyright ©; 2021, OOO "Эко-Вектор"Copyright ©; 2021, Eco-Vector2021Eco-VectorOOO "Эко-Вектор"Eco-Vectorhttps://journals.eco-vector.com/pavlovj/article/view/58095

One of the most severe complications of narcotic drugs misuse are induced psychotic disorders. Their frequency is varies from 5.2 to 100% and depends on the type of drug. This review provides current data and discussion on the similarities and differences between induced psychosis and schizophrenia. Possible interaction of pathogenic pathways, the possibility of differentiation at the clinical level and the main difficulties in clear diagnostic are discussed. The problem of transformation of induced psychoses into schizophrenia and the significance of differentiated treatment are also considered.

Одним из наиболее тяжелых осложнений злоупотребления наркотическими вещества являются индуцированные психотические расстройства. Частота их встречаемости варьирует от 5,2 до 100% и зависит от типа наркотического вещества. В настоящем обзоре приведены актуальные данные и дискуссия о сходствах и различиях индуцированных психозов и шизофрении. Обсуждаются возможные общие патогенетические пути возникновения, возможности дифференциации на клиническом уровне и основные затруднения при этом. Также рассматривается проблема трансформации индуцированных психозов в шизофрению и значимость дифференцированной тактики лечения.

药物滥用的一个最严重的并发症是诱发性精神病。它们的发生频率从5.2％到100％不等，取决于药物的类型。本审查报告提供了关于诱导性精神病和精神分裂症的相似性和差异的相关数据和讨论。讨论了可能的共同致病途径、临床差异的可能性以及在这方面的主要困难。还讨论了将诱导精神分裂症转变为精神分裂症的问题以及区别对待治疗策略的重要性。

substance induced psychosesschizophreniasubstance-related disordersиндуцированные психозышизофрениянаркомании诱发性精神病精神分裂症吸毒成瘾。World Drug Report 2020 (United Nations publication, Sales №E.20.XI.6). Available at: https://wdr. unodc.org/wdr2020/field/WDR20_BOOKLET_6.pdf Accessed: 2020 July 02.World Drug Report 2020 (United Nations publication, Sales №E.20.XI.6). Available at: https://wdr.unodc.org/wdr2020/field/WDR20_BOOKLET_6.pdf Accessed: 2020 July 02.European Drug Report 2020: Trends and Developments. Luxembourg: Publications Office of the European Union; 2020.Koshkina EA, Val’kova UV, Smirnovskaya MS. Sovremennyye trendy razvitiya narkologicheskoy situatsii. In: Psikhicheskoye zdorov’ye cheloveka i obshchestva. Aktual’nyye mezhdistsiplinarnyye problemy; 30 Oct 2017; Moscow. Moscow; 2018. (In Russ).Кошкина Е.А., Валькова У.В., Смирновская М.С. Современные тренды развития наркологической ситуации. В сб.: Психическое здоровье человека и общества. Актуальные междисциплинарные проблемы; 30 октября 2017; Москва. М.; 2018.Li EA, Koren SV. COVID-19 pandemic and drug users. Journal of Addiction Problems. 2020;(6):72-83. (In Russ).Ли Е.А., Корень С.В. Пандемия COVID-19 и наркопотребители // Вопросы наркологии. 2020. №6. С. 72-83.Vallersnes OM, Dines AM, Wood DM, et al. Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry. 2016;16:293. doi:10.1186/s12888-016-1002-7Vallersnes O.M., Dines A.M., Wood D.M., et al. Psychosis associated with acute recreational drug toxicity: a European case series // BMC Psychiatry. 2016. Vol. 16. P. 293. doi:10.1186/s12888-016-1002-7Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of psychotic symptoms in substance users:Smith M.J., Thirthalli J., Abdallah A.B., et al. Prevalence of psychotic symptoms in substance users: a comparison across substances // Comprehensive Psychiatry. 2009. Vol. 50, №3. P. 245-250. doi:10.1016/j.comppsych.2008.07.009a comparison across substances. Comprehensive Psychiatry. 2009;50(3):245-50. doi:10.1016/j.comp psych.2008.07.009Lecomte T., Dumais A., Dugré J.R., et al. The prevalence of substanceinduced psychotic disorder in methamphetamine misusers: A metaanalysis // Psychiatry Research. 2018. Vol. 268. P. 189-192. doi:10.1016/j.psychres.2018.05.033Lecomte T, Dumais A, Dugré JR, et al. The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Research. 2018;268:189-92. doi:10.1016/j.psychres.2018.05.033Hobbs M., Kalk N.J., Morrison P.D., et al. Spicing it up - synthetic cannabinoid receptor agonists and psychosis a systematic review // European Neuropsychopharmacology. 2018. Vol. 28, №12. P. 1289-1304. doi:10.1016/j.euroneuro.2018.10.004Hobbs M, Kalk NJ, Morrison PD, et al. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review. European Neuro-psychopharmacology. 2018;28(12):1289-304. doi:10. 1016/j.euroneuro.2018.10.004Ragazzi T.C.C., Shuhama R., Menezes P.R., et al. Cannabis use as a risk factor for psychoticlike experiences: A systematic review of nonclinical populations evaluated with the Community Assessment of Psychic Experiences // Early Intervention in Psychiatry. 2018. Vol. 12, №6. P. 1013-1023. doi:10.1111/eip.12693Ragazzi TCC, Shuhama R, Menezes PR, et al. Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. Early Intervention in Psychiatry. 2018;12(6):1013-23. doi:10.1111/eip.12693Roncero C., Abad A.C., Padilla-Mata A., et al. Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse // Current Neuropharmacology. 2017. Vol. 15, №2. P. 315-323. doi:10.2174/1570159X14666160324144912Roncero C, Abad AC, Padilla-Mata A, et al. Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse. Current Neuropharmacology. 2017;15(2):315-23. doi:10.2174/1570159X14 6661 60324144912Tatetsu S., Goto A., Fujiwara T. Psychostimulant toxicosis. Tokyo: Igakushoin; 1956.Tatetsu S, Goto A, Fujiwara T. Psychostimulant toxicosis. Tokyo: Igakushoin; 1956.Murray R.M., Paparelli A., Morrison P.D., et al. What can we learn about schizophrenia from studying the human model, druginduced psychosis? // American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics. 2013. Vol. 162, №7. P. 661-670. doi:10.1002/ajmg.b.32177Murray RM, Paparelli A, Morrison PD, et al. What can we learn about schizophrenia from studying the human model, drug-induced psychosis? American Journal of Medical Genetics. Part B: Neuro-psychiatric Genetics. 2013;162(7):661-70. doi:10.1002/ ajmg.b.32177Ghose S. Substance-Induced Psychosis: An Indicator of Development of Primary Psychosis? // The American Journal of Psychiatry. 2018. Vol. 175, №4. P. 303-304. doi:10.1176/appi.ajp.2018.17121395Ghose S. Substance-Induced Psychosis: An Indicator of Development of Primary Psychosis? The American Journal of Psychiatry. 2018;175(4):303-4. doi:10.1176/appi.ajp.2018.17121395Менделевич В.Д. Психотические расстройства в результате употребления наркотиков: современное состояние проблемы // Наркология. 2014. Т. 13, №7. P. 93-100.Mendelevich VD. Psychotic disorders due to drug use: current state of the problem. Narcology. 2014; 13(7):93-100. (In Russ).Логутенко Р.М. Гетероагрессивное и суицидальное поведение больных параноидной шизофренией с бредом одержимости // Наука молодых (Eruditio Juvenium). 2015. №4. С. 104-110.Logutenko RM. Heteroaggressive and suicidal behavior of patients with paranoid schizophrenia with delusions of obsession. Nauka Molodykh (Eruditio Juvenium). 2015;(4):104-10. (In Russ).Fiorentini A., Volonteri L.S., Dragogna F., et al. Substance-Induced Psychoses: A Critical Review of the Literature // Current Drug Abuse Reviews. 2011. Vol. 4, №4. P. 228-240. doi:10.2174/18744 73711104040228Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-Induced Psychoses: A Critical Review of the Literature. Current Drug Abuse Reviews. 2011;4 (4):228-40. doi:10.2174/1874473711104040228Howes O.D., Kambeitz J., Kim E., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment // Archives of General Psychiatry. 2012. Vol. 69, №8. P. 776-786. doi:10. 1001/archgenpsychiatry.2012.169Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Archives of General Psychiatry. 2012;69(8):776-86. doi:10.1001/archgen psychiatry.2012.169Kegeles L.S., Abi-Dargham A., Zea‐Ponce Y., et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implica-tions for schizophrenia // Biological Psychiatry. 2000. Vol. 48, №7. P. 627-640. doi:10.1016/S0006-3223(00)00976-8Kegeles LS, Abi-Dargham A, Zea‐Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biological Psychiatry. 2000;48 (7):627-40. doi:10.1016/S0006-3223(00)00976-8McCutcheon R.A., Krystal J.H., Howes O.D. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment // World Psychiatry. 2020. Vol. 19, №1. P. 15-33. doi:10.1002/wps.20693McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020; 19(1):15-33. doi:10.1002/wps.20693Ham S., Kim T.K., Chung S., et al. Drug Abuse and Psychosis: New Insights into Druginduced Psychosis // Experimental Neurobiology. 2017. Vol. 26, №1. P. 11-24. doi:10.5607/en.2017.26.1.11Ham S, Kim TK, Chung S, et al. Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology. 2017;26(1):11-24. doi:10.5607/en.2017.26.1.11Khokhar J.Y., Todd T.P. Behavioral predictors of alcohol drinking in a neurodevelopmental rat model of schizophrenia and cooccurring alcohol useKhokhar JY, Todd TP. Behavioral predictors of alcohol drinking in a neurodevelopmental ratdisorder // Schizophrenia Research. 2018. Vol. 194. P. 91-97. doi:10.1016/j.schres.2017.02.029model of schizophrenia and co-occurring alcohol use disorder. Schizophrenia Research. 2018;194: 91-7. doi:10.1016/j.schres.2017.02.029Brunette M.F., Mueser K.T., Babbin S., et al. Demographic and clinical correlates of substance use disorders in first episode psychosis // Schizophrenia Research. 2018. Vol. 194. P. 4-12. doi:10.1016/j. schres.2017.06.039Brunette MF, Mueser KT, Babbin S, et al.Martinotti G., De Risio L., Vannini C., et al. Substancerelated exogenous psychosis: a postmodern syndrome // CNS Spectrums. 2020. Vol. 1-8. doi: 10.1017/S1092852920001479Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research. 2018;194:4-12. doi:10.1016/j. schres.2017.06.039Caton C.L.M., Drake R.E., Hasin D.S., et al. Differences Between Early-Phase Primary Psychotic Disorders With Concurrent Substance Use and SubstanceInduced Psychoses // Archives of General Psychiatry. 2005. Vol. 62, №2. P. 137-145. doi:10.1001/archpsyc.62.2.137Martinotti G., De Risio L., Vannini C., et al. Substance-related exogenous psychosis: a postmodern syndrome. CNS Spectrums. 2020;1-8. doi:10.1017/S1092852920001479Caton C.L.M., Hasin D.S., Shrout P.E., et al. Stability of earlyphase primary psychotic disorders with concurrent substance use and substanceinduced psychosis // The British Journal of Psychiatry. 2007. Vol. 190, №2. P. 105-111. doi:10.1192/bjp.bp.105.015784Caton CLM, Drake RE, Hasin DS, et al. Differences Between Early-Phase Primary Psychotic Disorders With Concurrent Substance Use and Substance-Induced Psychoses. Archives of General Psychiatry. 2005;62(2):137-45. doi:10.1001/archpsyc.62.2.137Mauri M., Di Pace C., Reggiori A., et al. Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up // Asian Journal of Psychiatry. 2017. Vol. 29. P. 117-122. doi:10.1016/j.ajp.2017.04.014Caton CLM, Hasin DS, Shrout PE, et al. Stability of early-phase primary psychotic disorders with con-current substance use and substance-induced psychosis. The British Journal of Psychiatry. 2007; 190(2):105-11. doi:10.1192/bjp.bp.105.015784Weibell M.A., Joa I., Bramness J., et al. Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area // BMC Psychiatry. 2013. Vol. 13. P. 319. doi:10.1186/1471-244X-13-319Mauri M, Di Pace C, Reggiori A, et al. Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up. Asian Journal of Psychiatry. 2017; 29:117-22. doi:10.1016/j.ajp.2017.04.014Crebbin K., Mitford E., Paxton R., et al. First episode druginduced psychosis: a medium term fol-low up study reveals a high risk group // Social Psychiatry and Psychiatric Epidemiology. 2009. Vol. 44, №9. P. 710-715. doi:10.1007/s00127-008-0490-2Weibell MA, Joa I, Bramness J, et al. Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry. 2013;13:319. doi:10.1186/1471-244X-13-319Fraser S., Hides L., Philips L., et al. Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people // Schizophrenia Research. 2012. Vol. 136, №1-3. P. 110-115. doi:10.1016/j.schres. 2012.01.022Crebbin K, Mitford E, Paxton R, et al. First episode drug-induced psychosis: a medium term follow up study reveals a high risk group. Social Psychiatry and Psychiatric Epidemiology. 2009;44(9):710-5. doi:10.1007/s00127-008-0490-2Пятаева И.В.Куташов В.А.Хабарова Т.Ю. Дифференциальная диагностика эндогенных и интоксикационных (солевых) психозовЦентральный научный вестник. 2016.Fraser S, Hides L, Philips L, et al. Differentiating first episode substance induced and primary psy-chotic disorders with concurrent substance use in young people. Schizophrenia Research. 2012;136(1-3): 110-5. doi:10.1016/j.schres.2012.01.022Дубатова И.В., Стоякин И.В., Карнаух К.А., и др. Анализ клинических проявлений и особенности терапии психотических расстройств у потребителей дизайнерских наркотиков // Главный врач Юга России. 2018. №1. С. 52-56.Piataeva IV, Kutashov VA, Khabarova TY. Differential diagnosis of endogenous and substance-induced (salt) psychosis. Central Science Bulletin. 2016;1(16):30-2. (In Russ).Quattrone D., Ferraro L., Tripoli G., et al. Daily use of highpotency cannabis is associated with more positive symptoms in firstepisode psychosis patients: the EU-GEI case – control study // Psychological Medicine. 2020. Vol. 1-9. doi:10.1017/ S0033291720000082Dubatova I, Stojakin I, Karnauh K, et al. The analysis of clinical manifestations and peculiarities of psychotic disorders therapy in consumers of designer drugs. Glavnyy Vrach Yuga Rossii. 2018;(1): 52-6. (In Russ).Martinotti G., Di Nicola M., Quattrone D., et al. Novel psychoactive substances and induced phenomena in psychopathology: the lysergic psychoma // Journal of Psychopathology. 2015. Vol. 21. P. 400-405.Quattrone D., Ferraro L., Tripoli G., et al. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case – control study. Psychological Medicine. 2020;1-9. doi:10.1017/S0033291720000082Murray R.M., Quigley H., Quattrone D., et al. Traditional marijuana, highpotency cannabis and synthetic cannabinoids: increasing risk for psychosis // World Psychiatry. 2016. Vol. 15, №3. P. 195-204. doi:10.1002/wps.20341Martinotti G, Di Nicola M, Quattrone D, et al. Novel psychoactive substances and induced phenomena in psychopathology: the lysergic psychoma. Journal of Psychopathology. 2015;21: 400-5.Halpern J.H., Lerner A.G., Passie T. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD // Current Topics in Behavioral Neurosciences. 2018. Vol. 36. P. 333-360. doi:10.1007/7854_2016_457Murray RM, Quattrone D, Natesan S, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? The British Journal of Psychiatry. 2016;209(5):361-5. doi:10.1192/bjp.bp.116.182683Litjens R.P.W., Brunt T.M., Alderliefste G.-J., et al. Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases // European Neuropsychopharmacology. 2014. Vol. 24, №8. P. 1309-1323. doi:10.1016/j.euroneuro.2014.05.008Halpern JH, Lerner AG, Passie T. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. Current Topics in Behavioral Neurosciences. 2018;36:333-60. doi:10.1007/7854_2016_457Lev-Ran S., Feingold D., Rudinski D., et al. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation: Schizophrenia and HPDD: Clinical Characteristics // The American Journal on Addictions. 2015. Vol. 24, №3. P. 197-199. doi:10.1111/ajad.12204Litjens RPW, Brunt TM, Alderliefste G-J, et al. Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. European Neuropsychopharmacology. 2014;24(8):1309-23. doi:10.1016/j.euroneuro.2014.05.008Starzer M.S.K., Nordentoft M., Hjorthøj P. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis // The American Journal of Psychiatry. 2018. Vol. 175, №4. P. 343-350. doi:10.1176/appi.ajp.2017.17020223Lev-Ran S, Feingold D, Rudinski D, et al. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation: Schizophrenia and HPDD: Clinical Characteristics. The American Journal on Addictions. 2015;24(3):197-9. doi:10.1111/ajad.12204Kendler K.S., Ohlsson H., Sundquist J., et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample // The American Journal of Psychiatry. 2019. Vol. 176, №9. P. 711-719. doi:10.1176/appi.ajp.2019.18101217Starzer MSK, Nordentoft M, Hjorthøj P. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. The American Journal of Psychiatry. 2018; 175 (4):343-50. doi:10.1176/appi.ajp.2017.17020223Niemi-Pynttäri J.A., Sund R., Putkonen H., et al. Substance-Induced Psychoses Converting Into Schizophrenia: A Register-Based Study of 18,478 Finnish Inpatient Cases // The Journal of Clinical Psychiatry. 2013. Vol. 74, №1. P. e94-e99. doi:10.4088/JCP.12m07822Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced PsychoticHjorthøj P., Starzer M.S.K., Benros M.E., et al. Infections as a Risk Factor for and Prognostic Factor After Substance-Induced Psychoses // American Journal of Psychiatry. 2020. Vol. 177, №4. P. 335-341. doi:10.1176/appi.ajp.2019.19101047Disorder and Its Progression to Schizophrenia in a Swedish National Sample. The American Journal of Psychiatry. 2019;176(9):711-9. doi:10.1176/appi.ajp.2019.18101217Murrie B., Lappin J., Large M., et al. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Metaanalysis // Schizophrenia Bulletin. 2020. Vol. 46, №3. P. 505-516. doi:10.1093/schbul/sbz102Niemi-Pynttäri JA, Sund R, Putkonen H, et al. Sub-stance-Induced Psychoses Converting Into Schizophrenia: A Register-Based Study of 18,478 Finnish Inpatient Cases. The Journal of Clinical Psychia-try. 2013;74(1):e94-9. doi:10.4088/JCP.12m07822Gorelick D.A. Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review // Current Pharmaceutical Design. 2016. Vol. 22, №42. P. 6409-6419. doi:10.2174/1381612822666 160822150822Hjorthøj P, Starzer MSK, Benros ME, et al. Infections as a Risk Factor for and Prognostic Factor After Substance-Induced Psychoses. American Journal of Psychiatry. 2020;177(4):335-41. doi:10.1176/appi.ajp.2019.19101047Sulaiman A.H., Gill J.S., Said M.A., et al. A randomized, placebocontrolled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis // International Journal ofMurrie B, Lappin J, Large M, et al. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. 2020;46(3):505-16. doi:10.1093/schbul/sbz102Psychiatry in Clinical Practice. 2013. Vol. 17, №2. P. 131-138. doi:10.3109/13651501.2012.667116Gorelick DA. Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review. Current Pharmaceutical Design. 2016;22(42):6409-19. doi:10.2174/1381612822666160822150822Kekelidze Z.I., Klimenko T.V., Kozlov A.A., et al. Differential approaches to the treatment of acute psychosis due to the use of synthetic cannabinoids // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017. Vol. 117, №12. P. 21. doi:10.17116/jnevro201711712121-26Sulaiman AH, Gill JS, Said MA, et al. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. International Journal of Psychiatry in Clinical Practice. 2013;17(2):131-8. doi:10.3109/13651501.2012.667116Murray R.M., Quattrone D., Natesan S., et al. Should psychiatrists be more cautious about the longterm prophylactic use of antipsychotics? // The British Journal of Psychiatry. 2016. Vol. 209, №5. P. 361-365. doi:10.1192/bjp.bp.116.182683Kekelidze ZI, Klimenko TV, Kozlov AA, et al. Differential approaches to the treatment of acute psychosis due to the use of synthetic cannabinoids. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017; 117(12):21. doi:10.17116/jnevro201711712121-26Schoeler T., Monk A., Sami M.B., et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and metaanalysis // The Lancet. Psychiatry. 2016. Vol. 3, №3. P. 215-225. doi:10.1016/S2215-0366(15)00363-6Murray RM, Quigley H, Quattrone D, et al. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195-204. doi:10.1002/wps.20341Schoeler T., Monk A., Sami M.B., et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. The Lancet. Psychiatry. 2016;3(3):215-25. doi:10.1016/S2215-0366(15)00363-6